JP2022502399A5 - - Google Patents

Info

Publication number
JP2022502399A5
JP2022502399A5 JP2021516878A JP2021516878A JP2022502399A5 JP 2022502399 A5 JP2022502399 A5 JP 2022502399A5 JP 2021516878 A JP2021516878 A JP 2021516878A JP 2021516878 A JP2021516878 A JP 2021516878A JP 2022502399 A5 JP2022502399 A5 JP 2022502399A5
Authority
JP
Japan
Prior art keywords
cancer
platinum
antagonist
atr inhibitor
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021516878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/076116 external-priority patent/WO2020064971A1/en
Publication of JP2022502399A publication Critical patent/JP2022502399A/ja
Publication of JP2022502399A5 publication Critical patent/JP2022502399A5/ja
Pending legal-status Critical Current

Links

JP2021516878A 2018-09-26 2019-09-26 がんの治療のためのｐｄ−１アンタゴニスト、ａｔｒインヒビター、および白金製剤の組合せ Pending JP2022502399A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736699P 2018-09-26 2018-09-26
US62/736,699 2018-09-26
PCT/EP2019/076116 WO2020064971A1 (en) 2018-09-26 2019-09-26 Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2022502399A JP2022502399A (ja) 2022-01-11
JP2022502399A5 true JP2022502399A5 (https=) 2022-10-04

Family

ID=68159078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516878A Pending JP2022502399A (ja) 2018-09-26 2019-09-26 がんの治療のためのｐｄ−１アンタゴニスト、ａｔｒインヒビター、および白金製剤の組合せ

Country Status (12)

Country Link
US (1) US12227577B2 (https=)
EP (1) EP3856251B1 (https=)
JP (1) JP2022502399A (https=)
KR (1) KR20210066837A (https=)
CN (1) CN113286614A (https=)
AU (1) AU2019346012A1 (https=)
BR (1) BR112021004935A2 (https=)
CA (1) CA3114024A1 (https=)
ES (1) ES3009674T3 (https=)
IL (1) IL281670A (https=)
MX (1) MX2021003263A (https=)
WO (1) WO2020064971A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297842A (en) * 2020-05-11 2023-01-01 Astrazeneca Ab ATR inhibitors for cancer treatment
WO2024164089A1 (en) * 2023-02-09 2024-08-15 Repare Therapeutics Inc. Use of atr inhibitors in the treatment of cancers with high tumor mutational burden
WO2025233224A1 (en) * 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy
CN120884711B (zh) * 2025-09-29 2025-12-26 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 一种逆转卵巢癌顺铂耐药的药物制剂及其制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2798760A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
MX2013002084A (es) 2010-08-31 2013-05-09 Genentech Inc Biomarcadores y metodos de tratamiento.
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013049722A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
KR101764096B1 (ko) * 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SI2941432T1 (en) * 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
EP3077393A1 (en) 2013-12-06 2016-10-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
MX373102B (es) 2014-06-05 2020-04-17 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
RU2714233C2 (ru) * 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
US20180364240A1 (en) 2015-12-10 2018-12-20 Medimmune, Llc Methods for treatment and selection of patients responsive to immune mediated cancer therapy

Similar Documents

Publication Publication Date Title
JP2022502399A5 (https=)
JP2014508782A5 (https=)
TWI685341B (zh) 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途
Ahsan et al. Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts
US20180161302A1 (en) Pharmaceutical combination and uses thereof
JP2018531278A (ja) 癌のための併用療法
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
JP2018531278A6 (ja) 癌のための併用療法
EP3638228A1 (en) Compounds for treating tnbc
JP2015517523A5 (https=)
JP2023502876A5 (https=)
EP2721070A1 (en) Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
US20210023211A1 (en) Combination of anti-fgfr4-antibody and bile acid sequestrant
JP5579699B2 (ja) 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物
JP2021070702A (ja) 抗癌剤耐性の軽減、及び抗癌剤の感受性の増強のための医薬組成物及びその使用
WO2017176565A1 (en) Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CN101175495B (zh) 抗癌化合物的组合
EP4410283A1 (en) Triple combined therapy inhibiting egfr, raf1 and stat3 against pancreatic ductal adenocarcinoma
US12226454B2 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
US20150037336A1 (en) Combination of hb-egf binding protein and egfr inhibitor
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer
CN110402151A (zh) 三氟尿苷/盐酸替吡嘧啶、抗肿瘤铂配合物和免疫关卡调节剂之间的组合
RU2021110934A (ru) Комбинация антагониста pd-1, ингибитора atr и препарата платины для лечения злокачественного новообразования
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor